image: Jared W. Magnani, M.D., M.Sc., UPMC cardiologist and associate professor of medicine at the University of Pittsburgh view more
Credit: UPMC
PITTSBURGH – Patients diagnosed with depression were less likely to adhere to essential medical therapies following percutaneous coronary intervention (PCI) than those without depression, according to a new study published in JAMA Network Open by researchers at the University of Pittsburgh School of Medicine.
By reviewing claims data, researchers evaluated the connection between patients’ depression and their medication adherence over 12 months after undergoing PCI – a common procedure to open clogged coronary arteries in and around the heart. The medications prescribed to these patients include beta-blockers, antiplatelets and statins, all proven to reduce the likelihood of another heart attack or cardiovascular event.
Prior research has found that patients with depression have up to a three-fold increased risk of health problems or death after a heart attack than those without depression.
“It is well-appreciated that depression carries adverse cardiovascular risk. We wanted to understand better why that is the case,” said Jared W. Magnani, M.D., M.Sc., UPMC cardiologist and associate professor of medicine at Pitt. “We found that 10%-20% of individuals with depression were less likely to take their medicine after PCI – which is significant – because this group is at a higher risk for serious complications or dying from a heart attack.”
The study examined the records of more than 124,000 patients who underwent PCI and were diagnosed with depression by a medical provider. Magnani and his team used medical claims data that incorporated prescriptions filled at pharmacies to track if patients kept up with prescriptions.
Providers know that medication adherence is a critical component of cardiovascular disease prevention – but it is complex. Social factors, such as having money to cover medication costs or having to choose between medication copayments and household essentials, can affect whether a person is able to adhere to their medication. Pharmacy access can also be a challenge.
Magnani suggests that providers incorporate depression screenings to develop ways to improve medication adherence and health outcomes for patients with depression.
The study also highlights another known association: A significant proportion of people with coronary artery disease have or will develop depression; and people with depression have a four-fold increased risk of cardiovascular disease.
Study co-author Bruce Rollman, M.D., UPMC endowed chair and professor of medicine at Pitt, has led trials to treat depression following cardiac bypass surgery and after hospital discharge for heart failure.
“This study may help explain why cardiac patients with co-morbid depression tend to have higher rates of hospital readmissions and mortality than non-depressed cardiac patients,” Rollman said. “It also points to the need for organized health systems, such as UPMC, to routinely screen for and treat depression to maximize patients’ potential benefits from undergoing these high-cost cardiac procedures.”
Magnani noted that depression is a common condition, and the study results indicate that providers need to identify and address depression.
“We provide critical and sometimes lifesaving therapies to our patients with heart disease, and then prescribe therapies which we know can help them. If depression challenges or reduces their ability to adhere to those medications, then it is essential to address depression as part of cardiovascular care and treatment. Our team considers our findings an invitation to develop strategies to recognize depression as part of cardiovascular care,” Magnani noted.
The researchers acknowledged that the study did not provide insight into why adherence was diminished, but they hope to investigate those causes in the future to offer solutions.
Additional authors of this study are Matthew E. Lapa, M.D., Gretchen M. Swabe, M.S., Matthew F. Muldoon, M.D., and Rebecca C. Thurston, Ph.D., all of Pitt.
This research was supported by the National Institutes of Health's National Heart, Lung, and Blood Institute grants K24HL160527 and T32HL07560.
About the University of Pittsburgh School of Medicine
As one of the nation’s leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top recipients of funding from the National Institutes of Health since 1998. In rankings released by the National Science Foundation, Pitt is in the upper echelon of all American universities in total federal science and engineering research and development support.
Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region’s economy. For more information about the School of Medicine, see www.medschool.pitt.edu.
Journal
JAMA